Hyderabad:Aurobindo Pharma Limitedhas announcedthat Eugia Pharma B.V, a wholly owned stepdown subsidiary of the Company, has incorporated a new wholly owned subsidiary in Chile by the name of Eugia Pharma Chile SpA. In a regulatory filing with the BSE, Aurobindo Pharma stated that the newly incorporated entity will focus on expanding its pharmaceutical products business in Chile. According to the company, Eugia Pharma Chile SpA was incorporated onOctober 7, 2025, with an initial subscription to the share capital ofCLP 1,000,000 (USD 1,050), divided into 100 shares of CLP 10,000 each. Read also:Aurobindo Pharma Promoters Raise Rs 2,000 Crore via Structured Debt Headquartered in Hyderabad, India, Aurobindo Pharma Ltd. is a global pharmaceutical company with operations spanning active pharmaceutical ingredients (APIs), generics, and biosimilars. CuraTeQ Biologics is its wholly owned subsidiary focused on biosimilars for oncology and other therapeutic areas, enhancing Aurobindo’s footprint in biologics markets in Europe and beyond. Read also:Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!